HLA B leader study in psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study looks at a specific genetic marker (HLA B leader) in people with psoriatic arthritis compared to healthy individuals. It may help researchers understand how this gene affects the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have psoriatic arthritis diagnosed by a doctor using the CASPAR criteria.
- You must be a patient at CHU Amiens-Picardie hospital.
- You must be part of the hospital's psoriatic arthritis research group.
- You must be able to understand French.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene (Card14) in Egyptian patients with psoriasis or psoriatic arthritis. It may help understand why some people get these conditions and how they could be treated better.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
This study looks at how chronic inflammatory illnesses progress over time and how treatments affect symptoms and disease markers. You may be invited if you’re receiving care for certain bowel, joint, or skin inflammatory conditions at the hospital.
This study follows people with a first episode of peripheral (hand/foot/arm/leg) arthritis that seems to be psoriatic arthritis. It aims to improve understanding of early disease and may help guide more personalized care over time.
This study looks for certain immune markers (HLA antibodies) in stored blood samples from people with lupus. It may help doctors understand how the immune system behaves in lupus.
This study looks at how a body signal called IL-23 may drive inflammation in spondyloarthritis (including joints) using samples from your care. It may help researchers identify which body cells and targets are involved, and how treatments could work better for active disease.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.